Sort
16,300 grants matching “fatty liver disease”
Project 3: Non-invasive assessment of liver fibrosis stage and progression in obesity and diabetes: a Hispanic population study
$1,023,762Laura Beretta · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Treatment of Acute Coronary Syndromes with Recombinant LCAT Infusion
$1,022,830Brian Robert Krause · Alphacore Pharma, Llc · R44 · FY2010 · HL
National Resource for Advanced NMR Technology
$1,021,908Robert Schurko · Florida State University · RM1 · FY2025 · GM
Clinical Research on Nonalcoholic Fatty Liver Disease
$1,021,433Joel Edward Lavine · Columbia University Health Sciences · U01 · FY2011 · DK
FETAL BODY COMPOSITION AND VOLUMES STUDY
$1,019,576Wesley Lee · Baylor College Of Medicine · N01 · FY2018 · HD
In Vivo Proof of Concept and Target Identification Using Small Molecule Stimulators of Brown Adipogenesis
$1,018,644Olivier Boss · Energesis Pharmaceuticals, Inc. · R44 · FY2021 · DK
Administrative Core
$1,018,230Craig J McClain · University Of Louisville · P20 · FY2025 · GM
Multi-omics Studies of Childhood Complex Traits in Diverse Populations
$1,017,724Neil Hanchard · National Human Genome Research Institute · ZIA · FY2021 · HG
Whole Genome and Whole Exome Sequencing to Identify Genes for Type 2 Diabetes and Obesity
$1,016,641Leslie J Baier · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Immunologic Mechanisms of Alcoholic Liver Disease
$1,014,707Bin Gao · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2015 · AA
Innate immunity and cytokines in liver diseases
$1,014,707Bin Gao · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2015 · AA
Molecular signatures for liver cancer diagnosis and treatment stratification
$1,013,528Xin Wang · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Effects of Intermittent Energy Restriction on Intra-Abdominal Fat and the Gut Microbiome: A Randomized Trial
$1,013,085Loic Le Marchand · University Of Hawaii At Manoa · R01 · FY2025 · CA
Liver Cancer Disparities in Alaska Native and American Indian People
$1,011,489George Ioannou · University Of Washington · P20 · FY2021 · CA
Mechanisms of Fibrosis in Asthma and Other Fibroproliferative Diseases
$1,010,482Thomas Wynn · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
A novel approach to treat non-alcoholic steatohepatitis (NASH)
$1,008,980Cynthia Arbeeny · Mitotherapeutix, Llc · R44 · FY2023 · DK
Administrative Core
$1,008,427Michael I Goran · Children'S Hospital Of Los Angeles · P50 · FY2025 · MD
Mechanisms of Therapy and Model Development in Viral Hepatitis and Liver Diseases
$1,008,066T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)
$1,006,217David W Crabb · Indiana University Indianapolis · U01 · FY2014 · AA
Novel Cannabinoid Receptor Modulators
$1,004,709Malliga Iyer · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2021 · AA
A Novel Peptide Therapeutic for Obesity
$1,000,985Neil A Fanger · Virtici, Llc · R44 · FY2017 · DK
Regulation Of Intracellular Iron Metabolism
$1,000,829Tracey A. Rouault · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2012 · HD
Non-invasive staging of Metastasis by Precision MRI
$1,000,000Yiting Xu · Inlighta Biosciences, Llc · R44 · FY2023 · CA
Hepatoselective Dihydrozuinolizone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection
$1,000,000Yanming Du · Harlingene Life Sciences Llc · R42 · FY2025 · AI
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
$999,999Robert Paul Myers · Orsobio, Inc. · R44 · FY2023 · DK